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Optogenetics is an elegant approach of precisely controlling andmonitoring the biological
functions of a cell, group of cells, tissues, or organs with high temporal and spatial
resolution by using optical system and genetic engineering technologies. The field
evolved with the need to precisely control neurons and decipher neural circuity and
has made great accomplishments in neuroscience. It also evolved in cardiovascular
research almost a decade ago and has made considerable progress in both in vitro
and in vivo animal studies. Thus, this review is written with an objective to provide
information on the evolution, background, methodical advances, and potential scope of
the field for cardiovascular research and medicine. We begin with a review of literatures
on optogenetic proteins related to their origin, structure, types, mechanism of action,
methods to improve their performance, and the delivery vehicles and methods to
express such proteins on target cells and tissues for cardiovascular research. Next,
we reviewed historical and recent literatures to demonstrate the scope of optogenetics
for cardiovascular research and regenerative medicine and examined that cardiac
optogenetics is vital in mimicking heart diseases, understanding the mechanisms of
disease progression and also in introducing novel therapies to treat cardiac abnormalities,
such as arrhythmias. We also reviewed optogenetics as promising tools in providing
high-throughput data for cardiotoxicity screening in drug development and also in
deciphering dynamic roles of signaling moieties in cell signaling. Finally, we put forth
considerations on the need of scaling up of the optogenetic system, clinically relevant in
vivo and in silico models, light attenuation issues, and concerns over the level, immune
reactions, toxicity, and ectopic expression with opsin expression. Detailed investigations
on such considerations would accelerate the translation of cardiac optogenetics from
present in vitro and in vivo animal studies to clinical therapies.
Keywords: optogenetics, channelrhodopsins, opsin expression, cardiac pacing, arrhythmias, myocardial
infarction, cardiac electrophysiology, heterocellular coupling
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INTRODUCTION
The term “optogenetics” was first introduced in 2006 by
Deisseroth et al. and it broadly refers to an elegant approach that
utilizes genetic engineering and optical technology to control and
monitor biological functions of isolated or in situ cells, tissues,
organs or organisms, modified to express photosensitive proteins
(Deisseroth et al., 2006; Miesenböck, 2009; Entcheva, 2013; Jiang
et al., 2017; Koopman et al., 2017). The photosensitive proteins
are optical sensors or optical actuators which provide fluorescent
readout for changes in biological activities or allow light to
manipulate the cellular biological functions, respectively (Shui
et al., 2014; Jiang et al., 2017). Photosensitization of a specific cell
type, tissue, or organ of interest together with the application of
defined light stimulation and efficient light detection systems has
enabled optogenetics to perturb andmonitor biological functions
non-invasively with high spatiotemporal resolution (Boyden
et al., 2005; Park et al., 2014; Koopman et al., 2017). Biomedical
applications of optogenetics have evolved from neuroscience
with needs to precisely and rapidly control individual cells
in a vertebrate brain for deciphering the neural circuitries
underlying behavior and diseases, replacing approaches which
were not precise enough to target specific neuron populations,
were highly invasive, or were too slow in kinetics (Boyden
et al., 2005; Zhang et al., 2010; Mei and Zhang, 2012; Guru
et al., 2015). Historically, the concept of optogenetics was
conceived for neuroscience in 1979 with the suggestion from
Francis Crick on the potential utility of light in providing rapid
spatiotemporal control for targeting specific neurons; however,
during that time neuroscientists did not know methods to apply
such photosensitive proteins in neuroscience (Deisseroth, 2011).
Nevertheless, microbiologists had already known during that
time on the existence of photosensitive proteins which regulates
ion flow across the plasma membrane in some microorganisms
(Oesterhelt and Stoeckenius, 1971; Matsuno-Yagi andMukohata,
1977; Deisseroth, 2011). The seminal development in the field
evolved with a pioneering study by Nagel et al. (2003) which
demonstrated the feasibility to express microbial opsins, a light-
sensitive ion channel protein, in non-excitable mammalian
cells and enable fast, light-induced cell depolarization by tens
of mV. Similarly, another pioneering study by Boyden et al.
(2005) demonstrated the efficacy of light in modulating the
electrical excitability of neurons with high spatial and temporal
resolution upon expression of microbial opsins in mammalian
neurons. These studies led to an unprecedented growth of
optogenetics in different areas of neuroscience but the field
was largely unexplored for cardiovascular research at that time
(Deisseroth, 2011; Entcheva, 2013; Guru et al., 2015). Fortunately,
a new realm of cardiac optogenetics was laid by Bruegmann
et al. and Arrenberg et al., after their remarkable studies
on the successful applications of optogenetics for controlling
cardiomyocyte excitability both in vitro and in vivo of adult
mouse hearts and on the localization of pacemaker cells in the
developing zebrafish heart, respectively (Arrenberg et al., 2010;
Bruegmann et al., 2010; Entcheva, 2013).
In this review, we will begin with background on the
photosensitive proteins commonly used in optogenetics,
including their origin, chemical composition, structures, types,
and biophysical properties. Then, we will review common genetic
engineering approaches for expression of optogenetic proteins in
the target cells, tissues and organs. Finally, we will focus on the
potential applications of optogenetics for cardiovascular research
and medicine and will conclude with some considerations for
the translation of the field for clinical therapies.
OPTOGENETIC PROTEINS
Background
All organisms from archaebacteria to humans express
photoreceptor proteins, called rhodopsins, which provide
them the unique ability to “sense and respond” to light (Kato
et al., 2012; Ernst et al., 2013). However, based on the primary
sequence and mode of action, opsins are categorized as microbial
(type I) opsins and animal (type II) opsins; the former type
is found in microbes, such as archaea, eubacteria, fungi, and
algae, and the latter is found in animals and humans (Kato
et al., 2012). Microbial opsins include light-driven ion pumps,
such as bacteriorhodopsins (BRs) and halorhodopsins (HRs),
ion channels, such as channelrhodopsins (ChRs), and sensors,
such as sensory rhodopsin I and II (SRI and SRII) (Govorunova
et al., 2017). Upon light stimulation, these opsins mediate
transmembrane ionic currents and elicit specific biological
responses, such as phototaxis and photophobia, by coupling with
specific transducers (Nagel et al., 2003; Ernst et al., 2013). Animal
opsins indirectly mediate transmembrane ionic potential by
coupling to G-protein-mediated transduction pathways and are
primarily involved in dim light vision and circadian clock (Kato
et al., 2012; Ernst et al., 2013). Microbial opsins are commonly
used in optogenetic research because of their faster kinetics
and relative ease of genetic engineering of a single component
protein, compared to animal opsins (Guru et al., 2015).
Structure and Basic Mechanism
Microbial and animal rhodopsins share architectural similarities
and both are composed of seven transmembrane α-helices,
called opsins (also termed as apoproteins) and a photosensitive
chromophore, called retinal (Govorunova et al., 2017). Opsins
are designated as helix A to G in type I and as TM 1 to 7 in
type II, with their N-terminus on the outside of the cell and
their C-terminus on the inside (Ernst et al., 2013). On the other
hand, retinal, an aldehyde of vitamin A and derivative of β-
carotene, is covalently linked to ε-amino group of lysine side
chain on helix G or TM7 via retinal Schiff base (RSB) linkage
(Kato et al., 2012; Ernst et al., 2013). Upon illumination at
a specific wavelength, retinal in microbial rhodopsins usually
undergoes isomerization from all-trans to 13-cis that initiates a
series of cyclic reactions, known as photocycle, unique for each
microbial rhodopsin type (Bayraktar et al., 2012; Ernst et al.,
2013). This causes generation of unique photo-intermediates
that induces conformational change of proteins, which causes
channel opening, closing and ionic conductance of the rhodopsin
(Bayraktar et al., 2012; Ernst et al., 2013).
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Channelrhodopsin
Channelrhodopsin (ChR) was first discovered in unicellular
green algae Chlamydomonas reinhardtii where it provides the
algal eyespot the ability to sense and respond to light (Nagel et al.,
2002, 2003; Ernst et al., 2013). Thus, following light stimulation,
the primary depolarization in the plasma membrane of the
algal eyespot is transferred to the flagellar membrane, which
causes reorientation of algae toward light source and induces
phototaxis and photophobic responses (Ernst et al., 2013). The
green algae encode two forms of ChR, ChR1 and ChR2, both
are involved in light-mediated responses but their scope and
knowledge of mechanism of action were very limited until their
cloning by Nagel et al. in the Xenopus oocytes and mammalian
cells (Nagel et al., 2002, 2003). In 2003, Nagel et al. first cloned
channelopsin-2 (Chop2) in Xenopus oocytes, in the presence of
all-trans retinal, to determine if functional rhodopsin (having
covalently linked retinal, ChR2) can be obtained and also to
examine their functional characteristics (Nagel et al., 2003). They
noted that magnitude, direction and functional characteristics of
light-induced photocurrents from expressed Channelrhodopsin
(ChR2) are guided by both the cellular microenvironment and
the properties of blue light stimulus, such as intensity and
duration (Figures 1A–F; Nagel et al., 2003). ChR1 and ChR2 are
both common in optogenetics; however, the latter is getting more
attention since heterologous channelopsin-2 (Chop2) exhibit
capability to link with an endogenous all-trans-retinal and form
functional ChR2 in the mammalian system (Lin et al., 2009).
In addition, ChR2 exhibits fast onset kinetics (milliseconds),
show capability to reliably produce action potentials from high
frequency light pulses (milliseconds), and forms functional
complexes in most vertebrate systems without the need for
exogenous supplementation (due to the adequate availability of
all-trans-retinal); thus, ChR2 has remained as a prototypical and
very commonly used optogenetic tool (Mei and Zhang, 2012;
Entcheva, 2013).
Halorhodopsin
Halorhodopsin (HR) is found in halobacteria where it is utilized
for light-induced, inward-chloride transport across the outer
membrane (Lanyi, 1986). Thus, in physiological transmembrane
Cl− gradients, HR from an archaeon, Natronomonas pharaonis
(NpHR), is one of the commonly used optogenetic proteins
for generating hyperpolarizing, i.e., inhibitory currents in
mammalian cells (Guru et al., 2015; Wiegert et al., 2017). In this
regard, Han and Boyden (2007) demonstrated the feasibility of
NpHR to rapidly and reversibly silence targeted neurons using
yellow light pulses (560± 27.5 nm, 10mW/mm2). They observed
that hippocampal neurons, expressing NpHR, elicited outward
currents with fast kinetics (<20ms) when voltage-clamped and
produced rapid membrane hyperpolarization (∼100ms) when
current-clamped (Han and Boyden, 2007). Thus, their study
showed that upon heterologous expression of NpHR in targeted
regions and upon application of defined light stimulus, specific
population of neurons can be reversibly and reliably silenced
with high spatiotemporal resolution (Han and Boyden, 2007).
Since then several investigators have explored mechanisms to
generate enhanced versions of NpHR pumps (eNpHR) for safe
and improved membrane trafficking and to further improve
the ability to render mammalian cells electrically inexcitable
(Gradinaru et al., 2008; Guru et al., 2015). In the context of
cardiac optogenetics, Arrenberg et al. (2010) first reported the
use of eNpHR in zebrafish hearts to cause hyperpolarization
of myocardial cells and stop heart contractions. Since then
several investigators have reported the use of eNpHR and other
inhibitory optogenetic tools, such as achaerhodopsin (Arch), for
inhibition of cardiomyocytes activity (Abilez, 2012; Nussinovitch
et al., 2014; Park et al., 2014).
Optogenetic Sensors
Multiple optogenetic sensors are available to monitor
changes in electrical and biochemical parameters, such as
membrane voltage, calcium and chloride concentrations, pH,
neurotransmitter release, etc. (Tan et al., 2015; Jiang et al., 2017).
Structurally, these sensors are composed of a sensing domain
linked to a single or a pair of fluorescent proteins (Koopman
et al., 2017). Thus, when voltage, pH, calcium, or any other
physiological parameter changes, the conformation of the
sensing domain changes which in turn influences the optical
properties of the linked fluorescent proteins, such as changes
in their brightness or Förster resonance energy transfer (FRET)
(Koopman et al., 2017). Genetically encoded calcium indicators
(GECIs) have made great progress and are available with a wide
spectral sensitivity, binding affinity and sub-cellular localization
capability which have allowed subtle monitoring of calcium
changes both in in vivo and in situ settings, not attainable
with conventional optical dyes (Shui et al., 2014; Koopman
et al., 2017). Historically, Nakai et al. (2001) first developed
GECI, named GCaMP, by connecting N-terminus of circularly
permutated enhanced GFP (cpEGFP) to the M13 fragment of
myosin light chain kinase and by connecting the C terminus of
cpEGFP to calmodulin (CaM); thus, when calcium binds to CaM,
the conformation of cpEGFP changes altering the fluorescence
intensity and thereby allowing sensing of calcium changes. Since
then, GCaMP has remained as a popular calcium sensor in the
field; nevertheless, several GCaMP variants are being engineered
to account for issues with nuclear accumulation, toxicities and
dysregulated calcium signaling and also to provide enhanced
calcium sensing capacity (Nakai et al., 2001; Yang et al., 2018).
Next, genetically encoded voltage indicators (GEVIs), based
on bacterial rhodopsin or voltage sensing domain (VSD) of
voltage sensitive proteins, are also gaining greater attention in
the field (Koopman et al., 2017). VSD-based sensors evolved
with the discovery of VSD linked to phosphatase in the sea
squirt Ciona intestinalis (CiVSP) and with the first construction
and efficient plasma membrane localization of the voltage-
sensitive fluorescent probe (VSFP2.1) in mammalian cells by
Dimitrov et al. (Murata et al., 2005; Dimitrov et al., 2007;
Lundby et al., 2008; Akemann et al., 2009). The probe was
made by fusing VSD of C. intestinalis to a fluorescent reporter
and further through mutations to cause sensor activation within
the physiological range of the neuronal membrane potential
(Dimitrov et al., 2007; Lundby et al., 2008). Structurally, the
VSD of CiVSP contains four transmembrane helices (S1–S4)
linked to phosphatase while VSFP2.1 and its further engineered
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FIGURE 1 | Illustrations showing structural topology of Channelopsin-2 (Chop2) and the dependency of light-induced currents of Channelrhodopsin (ChR2) on both
cellular microenvironment and illumination parameters. Both variants of Chop2, full length Chop2-737 and truncated Chop2-315 (A), elicited large photocurrents upon
light stimulation when expressed in oocytes. The channel desensitizes during continuous blue light illumination (450 ± 25 nm), evidenced by the decay of the
photocurrent to a steady-state level (B), magnitude and direction of the photocurrent varies with the membrane potential (B), magnitude of photocurrents also differs
when kept in solution of different cations (C), magnitude of photocurrent also depends on the extracellular pH (D), and depolarization of cell membrane (millivolt) can
be achieved rapidly upon photosensitization with blue light illumination both in oocytes (E) and HEK293 cells (F). Reproduced with permission from Nagel et al. (2003)
and Chang Liao et al. (2015).
version VSFP2.3 (formed by eliminating specific amino acids)
are linked to fluorescent reporter proteins (such as cyan and
yellow fluorescent proteins) to indicate membrane potential
changes through FRET (Dimitrov et al., 2007; Lundby et al., 2008;
Akemann et al., 2009). In this aspect, both VSFP2.1 and VSFP2.3
exhibit excellent membrane targeting ability; however, improved
versions of VSFP are also being investigated specifically for
neuroscience application for their slower fluorescence readout
[e.g., time constant (>100ms) for fluorescence activation at
−10mV for VSFP2.3; (Lundby et al., 2008)].
Strategies to Improve Opsin Performance
Several opsin variants have evolved through targeted mutations
and chimera creation to meet specific optical and biological
requirements, such as spectral properties, photosensitivity,
photocurrents, kinetics, specific membrane trafficking capacity,
and temporal resolution (Ernst et al., 2013; Guru et al., 2015).
For instance, ultrafast opsins are evolving to provide faster
kinetics, step-function opsins are useful in extending the time
of channel open state while red shifted opsins are promising
for non-invasive and deeper tissue stimulation as red light
exhibits reduced scattering and absorption (Lin et al., 2013;
Klapoetke et al., 2014; Guru et al., 2015). Specifically, several ChR
variants have also evolved to address concerns of fast inactivation
with ChR2 (i.e., decline in the response upon repeated light
stimulation) and insufficient depolarization with ChR1 (i.e.,
limitation of the number of protons permeating through the
channel upon illumination; Lin et al., 2009). Lin et al. (2009)
first engineered ChR variants artificially by making chimeras of
channel opsins of ChR1 (Chop1) and ChR2 (Chop2) and by
further mutating the residues around retinal-binding pockets.
They found that: (i) the resulting chimera ChEF, with crossover
site at loop E-F, retained reduced inactivation of ChR1 but
allowed additional permeation of sodium and potassium ions, (ii)
ChIEF, a CHEF variant where isoleucine 170 is mutated to valine,
showed improved kinetics and, (iii) both these variants exhibited
membrane depolarization with higher temporal precision when
compared to ChR2 and produced consistent photo response
upon illumination at higher frequencies (>25 and 50Hz for
ChEF and ChIEF, respectively; Lin et al., 2009).
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Thus, several ChR2 variants have evolved to meet different
requirements, such as higher conductivity (ChR2-H134R),
higher calcium permeability and light sensitivity (CatCh),
increased expression and photocurrent (ChR2-XXL), and higher
tissue penetrability (ReaChR) (Boyle et al., 2018). For instance,
several red-shifted ChR variants have been engineered since
ChR2 typically show excitation maximum at 460 nm (Guru
et al., 2015). The first identified red-shifted opsin variant
VChR1, discovered inVolvox carteri, shows maximum excitation
at 535 nm; however, it is of limited utility due to its
reduced membrane trafficking and low photosensitivity in
mammalian systems (Lin et al., 2013; Guru et al., 2015). To
address such limitations, Lin et al. (2013) engineered red-
activatable channel rhodopsin (ReaChR) by using VChR1 as
a template and making several substitutions and mutations
in the protein domain to obtain improved red-shifted opsin
variant with enhanced membrane trafficking, faster kinetics,
improved photosensitivity, and a significantly higher red-shift
(maximum response ∼590–630 nm excitation). Interestingly,
they demonstrated that ReaChR enables optical control of neural
spiking in brains of mice with intact skulls (Lin et al., 2013).
On the contrary, Nyns et al. used 470 nm light pulse for
ReaChR-mediated depolarization and pacing in rat hearts, which
contradicts the earlier studies on the red-shifted response of
ReaChR (Nyns et al., 2016).
Similarly, new variants of GCaMP are evolving via mutations
to improve signal and membrane trafficking since conventional
GCaMP are hindered by their tendency to accumulate in the
nuclei, produce dysregulated calcium dynamics and cause cell
damage and toxicity (Shui et al., 2014; Yang et al., 2018).
In this regard, Yang et al. (2018) reported that GCaMP
containing CaM interferes with the L-type calcium channel that
introduces disruption in calcium signaling and gene expression.
Then, they engineered GCaMP-X, a GCaMP variant having
additional apoCaM-binding protection motif and an extra tag for
specific subcellular localization in the conventional GCaMP, and
demonstrated the robustness of the new variant which does not
disrupt calcium signaling (Yang et al., 2018). Similarly, several
variants of voltage sensors are evolving to improve the kinetics,
sensitivity, and reduce the signal artifacts when compared to
the results of the conventional voltage sensors (Mei and Zhang,
2012; Xu et al., 2017). GEVIs, based on VSD of C. intestinalis,
have evolved in various versions, such as from conventional
conjugation with FRET pairs (e.g., VSFP2.1and VSFP 2.3 for
nullifying motion and blood flow artifacts) to conjugation with
single fluorescent protein (for overcoming the broad spectrum
barriers associated with FRET system) and now further to
mutations in the fluorescent proteins and linker optimization
(e.g., VSFP3.1 for enhancing the sensitivity; Xu et al., 2017). A
summary on the optogenetic proteins, their source, functions and
potential applications in cardiovascular research and medicine is
provided in Table 1.
OPSIN EXPRESSION
Background
Various delivery methods are being explored to express
optogenetic proteins in cardiac cells and tissues. Such methods
TABLE 1 | A list of optogenetic proteins in cardiovascular research and medicine.
Optogenetic proteins Sources Functions and
applications
Channelrhodopsin (ChR) Unicellular algae
Chlamydomonas
reinhardtii
Light gated cation-selective
membrane channel,
provides algal eye ability to
sense light;
Depolarizing tool
in optogenetics
Halorhodopsin (HR) Halobacteria Induces light-gated inward
directed chloride transport;
Inhibitory tool
in optogenetics
GCaMP Calmodulin-based Calcium sensor
VSFP 2.1 Derived from voltage
Sensing domain of sea
Squirt Ciona intestinalis
Indicator of membrane
potential
VChR1 Multicellular algae
Volvox corteri
Red-shifted opsin variant;
Maximal excitation
at 535 nm
G-protein modulating
opsins
Natural and engineered Modulates cell signaling
JellyOp Jelly fish Gs-protein coupled
photoreceptor
Melanopsin Ganglion Cells of the
retina
Gq-coupled photoreceptor;
Regulation of
circadian rhythm
may employ direct delivery of genes (with or without vehicles)
and utilize physical cues, such as electric field (electroporation),
ultrasound waves (sonoporation), laser pulse (photoporation),
hydrodynamic pressure (hydroporation) etc., to enhance gene
delivery (Ramamoorth and Narvekar, 2015). Newer methods
are also investigating indirect photosensitization method via
transplantation of photosensitive cells in the target regions
(Gruber et al., 2018). A gene delivery method is ideal for cardiac
optogenetics if it is robust, efficient, stable, scalable, and also
provides sufficient packaging capacity but elicits minimal off-
target, inflammation, disease, toxicity, and mutagenesis (Wasala
et al., 2011; Lentz et al., 2012). Physical cues-mediated gene
delivery does not evoke concerns of mutations, immune, or
inflammatory reactions but poses threats on cell viability
since such methods cause irreversible pores in cell membrane
(Ramamoorth and Narvekar, 2015). Next, non-viral vehicles,
such as nanoparticles and dendrimers, also offer safe, easy and
cost-effective means of delivering genes but are hindered by low
delivery efficiency and low transgene expression (Ramamoorth
and Narvekar, 2015). On the other hand, viruses possess
extraordinary ability to invade living cells and organisms and
are thus widely used in gene delivery (Wasala et al., 2011).
Nevertheless, viruses are prone to cause disease, inflammation,
toxicity, and mutagenesis when used during gene delivery. Thus
newer strategies are focused to utilize viral invasion ability
but limit viral concerns by segregating viral components into
multiple constructs (Vannucci et al., 2013). Other strategies, such
as “tandem-cell unit” (TCU), are investigating the utility of in
vivo delivery of donor cells, such as stem cells or non-excitable
cells expressing optogenetic proteins, for electrical coupling
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to the native cardiomyocytes and allowing optical control of
the cardiomyocytes or intact heart using exogenously supplied
photosensitive cells (Jia et al., 2011).
Plasmid-Mediated Opsin Expression
Plasmids are extrachromosomal circular DNA molecules (sizes
<1 kbp to>200 kbp) and possess ability to replicate independent
of the host genome (Cooper et al., 2000; Williams and Kingston,
2011). Structurally, they are composed of: (1) a gene for antibiotic
resistance regulated by a promoter, (2) an origin of replication
which supports plasmid replication and survival, and (3) cloning
sites flanked by restriction endonuclease sites, which provide
sites for insertion of transgene constructs (Cooper et al., 2000;
Williams and Kingston, 2011; Hardee et al., 2017).
They are very common vectors for molecular cloning
in clinical trials because of their safety, negligible risk of
oncogenesis, reduced immunogenicity, and adequate packaging
capacity (Cooper et al., 2000; Williams and Kingston, 2011;
Hardee et al., 2017). Historically, Lin et al. first demonstrated
the ability of the heart to intake and express naked plasmid
DNA following direct myocardial injection; since then plasmid
has remained as a simple and common vector for gene delivery
in heart (Lin et al., 1990; Wasala et al., 2011). However,
plasmid vectors are mainly hindered by their low transduction
efficiency owing to their large size (Williams and Kingston,
2011; Hardee et al., 2017). Thus, several attempts are being
explored to improve their efficiency, such as: (1) length
shortening: to improve transduction efficiency, (2) physical
cues: to enhance penetration into the target cells, (3) cationic
vehicles: to protect from getting digested by nucleases and
to enhance cellular uptake, (4) modifications in the transgene
promoter and use of nuclear localization signals: to improve
target-specific transduction efficiency, etc. (Wasala et al., 2011;
Williams and Kingston, 2011; Ramamoorth and Narvekar, 2015;
Hardee et al., 2017). Nonetheless, these methods may render
plasmid susceptible to strand breakage or genomic integration,
reducing their therapeutic efficiency (Hardee et al., 2017), or
may pose safety concerns due to high voltage requirements
with electroporation (Williams and Kingston, 2011). Hence,
plasmids are widely engineered to carry viral components for
efficient opsin expression, examples of which are detailed in the
subsequent sections.
Viral Vector-Mediated Opsin Expression
Adenovirus
Adenoviruses host linear double-stranded DNA, with ∼30-kb
of the genome, and measure ∼70–100 nm (Wasala et al., 2011;
Lentz et al., 2012). Applications of recombinant adenovirus for
cardiac gene delivery started in the 1990s and have been applied
in animal studies and humans (Wasala et al., 2011). These viruses
are more efficient than plasmids for cardiac gene therapy and do
not integrate with the host genome (Wasala et al., 2011; Lentz
et al., 2012). However, prime concerns impeding the clinical
success of these vectors include toxicity, immunogenicity and
unstable gene expression (Wasala et al., 2011; Lentz et al., 2012).
Lentivirus
Background
From the last two decades, lentiviruses have been gaining
great attention for gene delivery in pre-clinical as well as in
clinical studies (Gandara et al., 2018). They are gaining wide
popularity for their well-defined characterization, safer new
generations, ability to effectively deliver genetic information
in both mitotic and non-mitotic cells, and provide long-term
and high transgene expression (Wasala et al., 2011; Gandara
et al., 2018). They measure ∼100 nm and consist of two single-
stranded RNA molecules, which undergo reverse transcription
and integrate into the host genome during their life cycle
(Lentz et al., 2012; Milone and O’doherty, 2018). Thus, gene
delivery systems using lentivirus minimize the risks associated
with viral particle formation and oncogenesis, but render their
machinery to effectively transduce and express target genes
(Vannucci et al., 2013; Gandara et al., 2018). One of such
milestones is the introduction of lenti-vector system designed to
reduce viral genomic load and segregate viral genome in multiple
constructs, namely vector construct, packaging construct and
envelop construct, so that chances of recombination, viral
particle formation, oncogenesis, and mutagenesis are minimized
or avoided (Durand and Cimarelli, 2011; Vannucci et al., 2013).
Lentiviral vector
The first generation of lentiviral system consists of three
constructs each in three plasmids, where a packaging construct
contains whole HIV genome except env, an envelope construct
encodes env, and a vector construct is flanked by two WT
long terminal repeats and it contains the transgene, with all
viral components removed except the encapsidation signal (psi)
and Rev recognition element (RRE) required for the export
of vector and transfer of un-spliced mRNA from nucleus to
cytoplasm (Durand and Cimarelli, 2011; Vannucci et al., 2013).
In the second generation, the vector is minimally modified
while the packaging construct is devoid of accessory genes
(such as vif, vpr, vpu, and nef that add no advantage for
vector production) but includes Tat and Rev; Tat is required
for LTR-driven transcription and Rev is needed for mRNA
transport (Dull et al., 1998; Durand and Cimarelli, 2011; Milone
and O’doherty, 2018). In the third generation, the vector is
made replication-incompetent and self-inactivating (SIN) type
by deleting U3 region of 5′LTR (to prevent promoter activity
of 5′LTR) and replacing it with an eukaryotic promoter (EP)
(to drive the transgene expression) and eliminating Tat from
the packaging construct but providing a fourth plasmid for Rev
(Durand and Cimarelli, 2011; Vannucci et al., 2013; Gandara
et al., 2018; Milone and O’doherty, 2018). In addition, the
third generation vector allows incorporation of additional short
non-coding sequence, poly purine central tract (cPPT), and
regulatory element, a woodchuck hepatitis post-transcriptional
regulatory element (W) for enhancing encapsidation efficiency
and improving post-transcriptional processing of transgene
RNA, respectively (Howarth et al., 2010; Vannucci et al., 2013).
Additionally, their ability to accommodate heterologous envelop
proteins “env” (pseudotyping) further enhances their tissue
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tropism and transduction efficiency (Durand and Cimarelli,
2011).
Opsin expression method using lentiviral vectors for
cardiovascular research
Abilez (2012) demonstrated the ability to optically stimulate
and inhibit human induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CM) colonies using second generation
lentiviral system. The tested lentiviral vectors were pLenti-EF1α-
ChR2-eYFP-WPRE(pLECYT) and pLenti-EF1α-NpHR1.0-
mCherry-WPRE(pLENMT), which were enveloped in lentiviral
plasmids (pLenti) and consist of lentiviral constructs composed
of human elongation factor 1α (EF1α) promoter, ChR2 or
NpHR1.0 transgene, YFP or mCherry fluorescent probes, and
WPRE post transcriptional regulatory element (Abilez, 2012).
Abilez first produced high titer of lentivirus by co-infecting
293FT (packaging cells) with pLECYT, pLENMT, pCMVR18.74
(containing gag and pol), pMD2.G (containing vesicular
stomatitis virus G protein VSVg, a pantropic envelope Durand
and Cimarelli, 2011, and calcium phosphate (for transfection)
(Abilez, 2012; Zacchigna et al., 2014). Such process would cause
release of viral particles in the supernatant via the budding
process from the packaging cells and the particles can be
collected and centrifuged for further concentration (Figure 2;
Howarth et al., 2010). Accordingly, Abilez transduced hiPSCs
with such viral particles, allowed transduced cells to differentiate
into cardiomyocytes and optically stimulated at days 15–30
of differentiation. It was reported that transduced colonies of
hiPSC-CM were optically controlled, showing synchronous
stimulation and inhibition upon appropriate light stimulation
(Abilez, 2012).
Adeno-Associated Virus
Background
AAV has emerged as one of the most promising gene delivery
systems for both pre-clinical and clinical gene therapies,
exceeding 170 clinical trials with excellent clinical safety data
(Wasala et al., 2011; Schnoedt and Buening, 2017). Both
lentivirus and AAV offer stable long-term and high expression
level, but the latter lowers mutagenesis concerns as they do not
integrate into the host genome (Lentz et al., 2012; Mei and
Zhang, 2012) and is non-pathogenic as it requires helper virus
for efficient replication (Schnoedt and Buening, 2017).
AAV vector
Structurally, AAV measure ∼18–25 nm and consist of a single
stranded DNA genome, spanning ∼4.7 kb pairs. The viral
genome consists of three open reading frames, rep and cap
regions codes for replication-related proteins and viral capsid
proteins (VP1, VP2, and VP3), respectively while AAP region
encodes protein for virion assembly (Zacchigna et al., 2014).
The viral genome is flanked by two ITR, each of 145-bp, and
are the only required elements for packaging genome into
the capsid (Schultz and Chamberlain, 2008; Zacchigna et al.,
2014). Thus, in a recombinant AAV (rAAV) vector, viral coding
region is replaced by transgene of interest (up to 5 kb) with
intact ITRs (Schultz and Chamberlain, 2008; Zacchigna et al.,
2014). In specific, rAAV vectors are produced by segregating
the genomic content between two plasmids, where AAV vector
plasmid will carry the transgene, flanked by ITRs, while a helper
plasmid will encode AAV capsid proteins (Howarth et al., 2010).
AAV serotype is categorized based on the amino acid sequence
of the capsid proteins, where AAV-9 serotype is reported to
exhibit robust cardiac tissue tropism compared to other serotypes
(Wasala et al., 2011; Lentz et al., 2012). However, the cardiac
transduction efficiency of these serotypes is additionally governed
by route of gene delivery, presence or absence of helper viral
genes and cell cycle status (mitotic vs. non-mitotic; Zacchigna
et al., 2014).
Opsin expression method using AAV vectors for
cardiovascular research
Vogt et al. (2015) utilized AAV vector AAV9-CAG-
hChR2(H134R)-mCherry (Penn Vector Core, University of
Pennsylvania) to deliver ChR2 gene in the hearts of wild-type
mice. They selected AAV9 serotype, ubiquitous promoter CAG
(chicken-β-actin promoter) and humanized and mutated ChR2
i.e., hChR2(H134R) in their vector to provide greater tropism
to cardiomyocytes, higher transduction efficiency, and larger
photocurrents, respectively, while m-Cherry was selected as
fluorescent probe (Nussinovitch and Gepstein, 2015; Vogt et al.,
2015). For transduction, they first diluted ∼2∗1011 genome
copies of AAV9-CAG-hChR2(H134R)-mCherry in 100 µl of
PBS and injected intravenously (left jugular vein) in anesthetized
CD1 wild-type mice (Vogt et al., 2015). They detected that
mCherry fluoresces ∼ 4–10 weeks in the whole mice hearts
and, upon dissociation, more than 50% of cardiomyocytes
were observed to be mCherry-positive. Interestingly, action
potentials were evoked upon stimulation with short pulses of
blue light (1ms, 5 mW mm−2) in the dissociated transduced
cardiomyocytes. They also reported that ventricular stimulations
were evoked on the transduced mice hearts by optical pacing
(shown by broad QRS complexes) and the responses were
dependent on the illumination parameters, such as light intensity
and irradiation area. These results depict the ability of AAV
vector in successful transduction of the optogenetic proteins in
the intact cardiomyocytes (Vogt et al., 2015).
Strategies to Enhance and Targeted
Transgene Expression
Structurally, transgenes should include promoters, introns,
protein coding sequence, and poly(A) site for successful gene
expression, where (1) promoters provide transcription start
site and transcription regulatory sequence to control transgene
expression both temporally and spatially, (2) introns play a
role in mRNA stabilization and translocation from nucleus to
the cytoplasm, (3) protein coding sequence enables ribosome
scan and recognize start and stop sites for mRNA, and (4)
poly(A) site forms the transcriptional stop signals (Brinster et al.,
1988; Huang and Gorman, 1990; Haruyama et al., 2009). Cell-
specific promoters provide restricted expression of the transgene
to the specific cell types or tissue regions of interest (Mei and
Zhang, 2012). However, some cell-specific promoters possess
long regulatory elements which may not be applicable with
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FIGURE 2 | A schematic illustration showing production of lentiviral vectors. Lentiviral vectors are produced via co-transfection of packaging constructs and shuttle
vector, containing the transgene, on packaging cell line (e.g., HEK293T). Viral particles are formed upon co-transfection and released into the supernatant via budding
process, which can be concentrated before transduction into target cells. Reproduced with permission from Howarth et al. (2010).
some gene delivery methods with limited packaging length,
such as AAV and lentivirus (∼2 kb for AAV and ∼5 kb for
lentivirus; Mei and Zhang, 2012; Guru et al., 2015). To eliminate
such shortcomings, strong ubiquitous promoters are utilized
for high opsin expression but the expression is made site-
specific by using conditional expression systems, such as Cre
recombinase (Mei and Zhang, 2012; Guru et al., 2015). Thus,
when viral vectors containing “floxed-stop” or “floxed-inverse”
cassettes are delivered, only the targeted cells, expressing the Cre
recombinase, will correct the orientation and allow expression
of the targeted gene, which enables cell-specific high expression
(Madisen et al., 2012; Guru et al., 2015). For instance, Zaglia
et al. (2015) selectively expressed ChR2 either on working
cardiomyocytes or on conducting cardiomyocytes by breeding
transgenic mice expressing double-floxed-ChR2 with strains
expressing Cre recombinase using promoter either for working
cardiomyocytes (MyHC-CRE) or conducting myocytes (Cx40-
Cre), respectively.
Next, dual vector strategy is being researched to address
concerns of small packaging limit for transgene expression
which allows single vector genome to be divided into two
independent virions that subsequently gets reconstituted (Wasala
et al., 2011; Mei and Zhang, 2012). Another concern is the
rate limiting second strand synthesis of ssDNA with AAV
which confers them relatively low transduction efficiency in
the absence of helper viral genes (Ferrari et al., 1996; Schultz
and Chamberlain, 2008). Self-complementary (scAAV) vectors
are being investigated to eliminate the dependence on rate-
limiting second strand synthesis step, where these vectors contain
centrally located mutated ITR and two copies of transgene
sequences, inverted and complementary to each that allow
genome to self-anneal (Lentz et al., 2012; Zacchigna et al., 2014).
In addition, approaches on the efficient and safe in vivo gene
delivery strategies, optimal dose requirements, andmodifications
on the vector design and vector variants for higher tropism and
resistance to neutralizing antibodies etc. are being explored to
enhance transgene expression for in vivo and clinical applications
(Chamberlain et al., 2017; Ishikawa et al., 2018).
POTENTIAL APPLICATIONS OF
OPTOGENETICS FOR CARDIOVASCULAR
MEDICINE
Cardiac Conduction System
Arrenberg et al. (2010) demonstrated that optical interrogation of
ChR2- and NpHR- expressing hearts of developing zebrafish will
provide a mechanism to map the time-dependent development
and convergence of cardiac conduction system. They illuminated
zebra fish hearts, from embryonic to larval stage (1–5 dpf), over
different heart regions with varying illumination surfaces and
light intensities in order to locate the distribution/ convergence
and the nature of the pacemaker cells of the conduction system
during their development. Illumination of larger area of venous
pole at 1 dpf stopped beating of whole heart while illumination
of right part of the sinoatrial ring stopped beating at 2 dpf,
since illumination would inhibit NpHR expressing pacemaker
cells and cause the heart to stop beating (Arrenberg et al., 2010).
Similarly, Zaglia et al. (2015) examined the scope of optogenetics
in assessing the function of Purkinje fibers in aminimally invasive
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manner in intact hearts because the availability of such a direct,
selected, and non-invasive manipulation of the conduction
system was very limited at that time. They developed transgenic
mouse models expressing ChR2 in Purkinje fibers, under the
control of Cre recombinase and cell-specific promoter (Cx-40)
(Cx-Cre mouse; Zaglia et al., 2015). They utilized LED source and
optical fibers for epicardial illumination of the Purkinje network.
They found that electrophysiological responses (e.g., ectopies)
were very dependent on the illumination site and such responses
were abolished upon ablation of Purkinje fibers, confirming
the correct targeting of ChR2 expression (Zaglia et al., 2015).
Thus, these studies show the great potential of optogenetics to
investigate and interrogate the role of cardiac conduction system
of an intact heart in a minimally invasive manner, both during
and after development.
Monitoring Electrophysiological Functions
Optical mapping of cardiac biological functions, such as
transmembrane voltage and calcium changes, provide
important insights on the physiological processes during
cardiac development, homeostasis and disease (Chang Liao et al.,
2015; Xu et al., 2017). Traditional methods of recording such
electrophysiological phenomena include: (1) surface electrodes
which are limited by their spatial resolution and (2) intracellular
methods, such as impaling electrodes and patch clamps, which
are invasive, time-consuming, and low throughput (Chang Liao
et al., 2015; Xu et al., 2017). Organic dyes, such as fluorescent
dyes that label specific intracellular ions (Ca, Mg, Na) and voltage
sensitive dyes, provide higher spatial resolution, higher temporal
resolution and high content optical imaging not possible with
traditional microelectrodes (Chang Liao et al., 2015; Koopman
et al., 2017). In addition, integration of optogenetics and such
fluorescent imaging allows for control of the functions of
multiple cardiac cells and also simultaneous mapping of their
biological signals non-invasively (Entcheva, 2013; Park et al.,
2014). Park et al. (2014) shows capability to monitor, control
and map action potential of neonatal rat ventricular myocytes by
expressing ChR2 or eNpHR3.0 and voltage-sensitive dye (PGH1)
and through concurrent opsin stimulation and fluorescence
excitation of such cells. An example of an optical system utilized
by Park et al. is illustrated in Figure 3A. Jia et al. also previously
demonstrated all optical system (with additional closed feedback
system) for contactless and precise optical actuation, control and
mapping of biological signals, such as calcium transients and
membrane potential (Jia et al., 2011). Appropriate selection of
dyes and optogenetic constructs is crucial in such optogenetic
system so that their absorption spectra do not infringe with one
other (Jia et al., 2011; Park et al., 2014). However, organic dyes,
such as voltage-sensitive dyes, are hindered by their chronic
toxicity, inability to perform repeated experiments on the same
sample over an extended period of time and the applicability
of such dyes for in vitro studies only (Chang Liao et al., 2015;
Koopman et al., 2017).
Optogenetic sensors, such as GEVIs and GECIs, can address
some of the aforementioned limitations with conventional
electrodes and organic dyes and provide precise means of
probing functions of intact heart cells in a minimally invasive
manner (Chang Liao et al., 2015; Koopman et al., 2017; Xu
et al., 2017). Specifically, genetically encoded voltage sensors
enable direct in vivo readout of the voltage signals, such
as action potential, of the intact cells (Xu et al., 2017). In
addition, when such sensors are integrated with optogenetic
actuators they provide all optics system, which enable precise
controlling and mapping of the electrical activity of opsin-
expressing intact cells and tissues (Park et al., 2014). In addition,
cell-specific promoters and sub-cellular specific motifs allow
targeted expression to specific cell types and sub-cellular regions,
respectively, that provide higher spatial resolution (Koopman
et al., 2017). Liao et al. established the first transgenic mouse
model expressing the voltage sensor VSFP2.3, under the control
of the cardiomyocyte-selective α-MHC promoter (Chang Liao
et al., 2015). They reported that transgene expression did
not elicit cardiotoxicity but produced highly reliable optical
recordings of cardiomyocyte-specific membrane voltage of
Langendorff-perfused transgenic mouse hearts and such optical
recordings were synchronous with the ECG recordings at both
normal and arrhythmic conditions (Figures 3B–D; Chang Liao
et al., 2015). The optical system by Liao et al. provides aminimally
invasive procedure for optical recordings of cardiomyocyte-
specific voltage changes in an intact transgenic mouse heart
and the components of the system, which includes light source,
excitation filter, optical fiber bundle, emission filter, and camera,
are detailed in Figure 3E (Chang Liao et al., 2015). These
studies suggest that targeted expression of optogenetic sensors
and appropriate optical system provide a valuable tool in
monitoring electrophysiological functions of the target cells, such
as cardiomyocytes, in a minimally invasive manner in both in
vitro and in vivo settings.
Manipulating Electrophysiological
Functions and Disease Models
Park et al. (2014) examined the feasibility of monitoring
and manipulating action potentials (lengthening or shortening
duration) of opsin-expressing cardiomyocytes using an all
optical system. They demonstrated that action potential duration
of ChR2- or eNpH3.0-sensitized monolayer of neonatal rat
ventricular myocytes can be reliably modulated, prolonged,
or dampened using light stimulus of appropriate wavelength,
frequency and intensity (Figure 4; Park et al., 2014). Next,
Govorunova et al. (2016) demonstrated an efficient approach
for shortening of cardiac action potential by using an anion
channelrhodopsin from Guillardia theta (GtACRs) which
provide selective and higher anion conductance to cause
cell inhibition with lower light intensity, when compared to
traditional halorhodopsin (NpHR). They found that action
potential duration of cultured NRVM was shortened to variable
extents by delivering pulsed light (510 nm) at different intervals
or of different intensities (e.g., 2.3–230 uW/mm2) during the
repolarization phase (Figure 4; Govorunova et al., 2016). These
results suggest that optogenetics potentially provide therapeutic
mechanisms in treating heart diseases arising from altered
electrophysiology, such as long QT syndrome. Many lethal
arrhythmias are result of pathological changes in action potential
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FIGURE 3 | An all optical system by Park et al. includes two LEDs for concurrent stimulation and fluorescence recording from monolayers of ChR2- or
eNpHR3.0-expressing neonatal rat ventricular myocyte (NRVM), stained with the voltage-sensitive dye PGH1, appropriate collimating lens, 253-channel fiber optic
bundle, photodetectors, and data acquisition system (A). The generation of optical cardiogram (OCG) waveforms in Langendorff-perfused transgenic mouse hearts
expressing the optogenetic voltage sensor VSFP2.3, under the control of the cardiomyocyte-selective MHC promoter, using fast camera system (frame rate 500Hz)
(B–D). OCG recordings were synchronous with the ECG recordings during sinus rhythm (B). The OCG and ECG recordings showed 1:1 capture during electric
pacing at physiological rate (10Hz) using point electrode (PE) (C). OCG also showed anisotropic spread of signal over time (C, below), reflecting the physiologic nature
of signal propagation. Both ECG and OCG reflected abnormal recordings following induction of ventricular arrhythmia (using 12.5-Hz 200-pulse train) and arrhythmic
regions can be located using OCG signal propagation images captured at regular time intervals (D) (Scale bars: 1mm). Fiber optic system (E, left) also tested to
record OCG signals from the intact hearts of transgenic mice, expressing VSFP2.3, in a minimally invasive manner. The fiber optic system consists of light source (a),
excitation filter (b), optical fiber bundle (c), emission filter (d), cameras for capturing CFP, and YFP fluorescence signals (e1 and e2) (E, middle: magnified image
showing tip of fiber bundle; right: image showing direct placement of fiber bundle against the functioning heart in situ). Reproduced with permission from Park et al.
(2014) and Chang Liao et al. (2015).
duration and very few drugs are capable of addressing such issues
without significant side effects (Park et al., 2014; Govorunova
et al., 2016; Boyle et al., 2018). Thus, optogenetics can be explored
as a novel tool to modulate electrophysiological functions, mimic
heart diseases and potentially treat such outcomes.
Pacing the Heart and Treating Arrhythmias
Background
Ischemic heart diseases, cardiomyopathies, channelopathies,
myocarditis, genetic abnormalities, and congenital defects may
manifest uncoordinated electrophysiological functions in the
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FIGURE 4 | Optogenetic manipulation of action potential duration using light stimuli of an appropriate wavelength. Action potential duration of ChR2-sensitized
cardiomyocytes can be prolonged upon application of blue light pulses during the repolarization phase of the cells and the increment in action potential duration is
dependent on the number of light pulses (A). On the contrary, action potential of cardiomyocytes expressing GtACRs, an anion channelrhodopsin, can be shorted
using green light pulses (510 nm), where the action potential shortening is dependent both on the instance of illumination and light intensity (B). Reproduced with
permission from Park et al. (2014) and Govorunova et al. (2016).
heart and often result to arrhythmias, which is one of the leading
causes of sudden cardiac arrest (Spartalis et al., 2018). Typically,
sudden cardiac death accounts for ∼50% of all cardiovascular
deaths wherein ventricular arrhythmias alone account for ∼80%
of sudden cardiac deaths occurring in public (Spartalis et al.,
2018). Anti-arrhythmic drugs, ion channel blockers, catheter
ablation, implantable electronic pacemakers and defibrillators are
some of the commonly adopted clinical methods for treating
cardiac arrhythmias (Ambrosi and Entcheva, 2014; Van Weerd
and Christoffels, 2016; Spartalis et al., 2018).
Electronic pacemaking is considered the first line treatment
of bradyarrhythmias and for resynchronization therapies. It
causes brief depolarization of a small group of cardiomyocytes
which consequently causes whole heart excitation (Bruegmann
et al., 2016). Cardioverters and defibrillators, on the other
hand, are considered for termination of malignant arrhythmias,
such as ventricular tachycardia and ventricular fibrillation, and
requires depolarization of a larger mass of cardiomyocytes and
larger energy when compared to that needed for heart pacing
(Zipes et al., 1975; Ambrosi and Entcheva, 2014; Bruegmann
et al., 2016). Although these devices are usually considered
safe and reliable, they also possess some inherent limitations
(Ambrosi and Entcheva, 2014). Electronic pacemakers require
invasive surgical procedure, repeated battery replacements and
are prone to device malfunctions and infections (Nussinovitch
and Gepstein, 2015). Defibrillators cause non-selective excitation
of nerves and muscles and deliver high energy electrical
shocks which may result in greater tissue damage, pain
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and discomfort that often lead to patient intolerance to the
procedure and increased mortality (Ambrosi and Entcheva,
2014; Bruegmann et al., 2016). These electrical procedures
also lead to irreversible electrochemical reactions which cause
release of toxic gases and change in tissue pH (Bruegmann
et al., 2010; Nussinovitch and Gepstein, 2015). Unfortunately,
patients with cardiac conduction abnormalities may need to
be treated frequently for a longer period of their life; hence,
application of such electrical therapies may be restricted because
of repeated cardioversion shocks, toxic gas release, myocardial
tissue damage, pain, and increased mortality associated with
the procedure (Boriani et al., 2000; Geller et al., 2003;
Bruegmann et al., 2010). Hence, there is an unmet clinical
need of a novel procedure that can be applied permanently
to treat cardiac conduction abnormalities in a rapid, precise,
controlled, less-traumatic, and shock-free manner (Nyns et al.,
2019).
Developments in the Field
Optogenetics hold significant potential as a novel therapeutic
procedure to treat conduction abnormalities as it allows light-
mediated targeted and controlled stimulation to address issues
associated with existing electrical therapies, such as non-
selective excitation, electric shocks, unwanted tissue damage,
and pain (Figure 5; Ambrosi and Entcheva, 2014). Historically,
Bruegmann et al. (2010) first demonstrated that an intact
transgenic mouse heart expressing ChR2 can be stimulated
rapidly by spatially confined blue light pulses. Specifically, they
showed that the heart rate could be entrained by short (1ms),
low-intensity (<10 mW/mm2) light pulses delivered to the
atria or ventricles and ventricular extrabeats were induced with
prolonged ventricular illumination (200ms; Bruegmann et al.,
2010). Thus, this study was the first to show the potential of
optogenetics in investigating the mechanisms and conditions
associated with cardiac pacing and arrhythmias (Bruegmann
et al., 2010).
Optogenetics also enables excitation of only a small number
of target cells. Thus, it may be useful in advancing current
pacemaker technology that uses ventricular pacing, rather
than direct, physiological His bundle pacing, due to the
physical constraints of pacing wire positioning (Nussinovitch and
Gepstein, 2015; Sharma et al., 2015; Boyle et al., 2018). Recent
computational and experimental studies show that optogenetics
will address such challenges by providing targeted stimulation
of opsin-expressing His bundle only, but not of the neighboring
cells, and also by lowering the energy requirements associated
with the procedure (Boyle et al., 2013, 2018; Zaglia et al., 2015).
Another concern with the conventional pacing procedure is
that it rely on single site ventricular pacing, an approach that
often alters or prolongs total ventricular activation time and
reduces ventricular contractile function and further deteriorates
systolic performance (Wilkoff et al., 2002). This concern has
been clinically addressed using biventricular pacing procedure,
an approach termed as cardiac resynchronization therapy (CRT),
but the procedure is impeded by the limited number of pacing
wires (Nussinovitch and Gepstein, 2015). To address these
shortcomings, Nussinovitch and Gepstein (2015) investigated
the potential of optogenetics for cardiac pacing and CRT in
rat hearts that were injected with a ChR2-AAV-9 vector at one
or more specific sites. They found that the heart rate could
be entrained by blue light (450 nm) pulses both in vivo and
ex vivo (Figure 6; Nussinovitch and Gepstein, 2015). Further,
they found that upon simultaneous photo stimulation of three
different opsin expressing sites in the left ventricle, the total
ventricular activation time was significantly lowered (14.8ms)
when compared to single-site right ventricular electrical pacing
(24.8ms) (Figure 6; Nussinovitch and Gepstein, 2015).
DC shock effectively terminates cardiac fibrillation, but the
unspecific delivery of high electrical shocks used for defibrillation
can cause greater tissue damage (Karagueuzian and Chen,
2001). Thus, there is a need for less damaging and low energy
defibrillation methods. Bruegmann et al. (2016) for the first time
examined the potential of optogenetic defibrillation in treating
ventricular tachycardia of intact hearts. They experimentally
demonstrated that anteroseptal epicardial illumination of the
ChR2 transgenic mouse hearts, using single light pulse (470 nm
wavelength, 0.4 mW/mm2 intensity, 143 mm2 illumination
area, and 1 s exposure duration), terminated electrically induced
sustained ventricular tachycardia (success rate ∼85%) (Figure 7;
Bruegmann et al., 2016). They also determined the illumination
parameters for ventricular tachycardia termination, such as an
effective illumination duration should capture total ventricular
tachycardia duration (80ms) while light intensity should be
increased (>0.4 mW/mm2) when the illumination area is
reduced (<143 mm2) (Figure 7; Bruegmann et al., 2016).
Concomitant in silico work showed that the same approach
in the human heart would require light pulses of longer
wavelength (669 nm) and higher intensity (>10 mW/mm2;
Bruegmann et al., 2016).
Similarly, Burton et al. (2015) and Crocini et al. (2016)
investigated possibilities in managing the heterogeneity of
the conduction system, such as the characteristic re-entrant
conduction waves, for efficient restoration of cardiac rhythm.
In specific, Crocini et al. induced and characterized ventricular
tachycardia in ChR2-expressing mouse hearts, loaded with
the voltage sensitive dye di-4-ANBDQPQ, and employed
mechanistic-based custom stimulation in an all optical system
to possibly inhibit re-entrant waves by refractories of ChR-
2 stimulated cardiomyocytes for optogenetic defibrillation
(Crocini et al., 2016). They compared the efficiencies of a
single point, a single barrier and a triple barrier stimulation
patterns were compared in terminating arrhythmias, and found
that the triple barrier was the most effective in interrupting
ventricular tachyarrythmias (Crocini et al., 2016). They also
found that although the success rates of triple barrier and
whole heart stimulation were comparable, the total irradiance
energy associated with each procedure were significantly different
(0.25 and 1 mJ, respectively), showing the therapeutic potential
of optogenetic-based cardioversion procedures (Crocini et al.,
2016). Zaglia et al. (2015) demonstrated the utility of optogenetics
for identifying specific heart regions, areas, cell numbers, and
cell types (His-Purkinje vs. working myocytes) that contribute to
arrythmogenesis following myocardial ischemia. These studies,
along with an excellent review paper by Pianca et al.
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FIGURE 5 | A schematic representation showing benefits of optogenetic stimulation over conventional electrical stimulation. Conventional electrical stimulation results
in an unspecific depolarization of myocardial cells, including nerve fibers, within the stimulated tissue volume resulting in pain and tissue injury. Optogenetics provides
restricted stimulation to opsin-expressing cells. Listed in the figure are cell-specific promoters Myosin Heavy Chain (MyHC), Connexin 40 (Cx40), and Tyrosine
Hydroxylase (TOH) that are used for targeted stimulation of opsin expressing cardiomyocytes, Purkinje fibers and sympathetic neurons, respectively. Reproduced and
adapted with permission from Pianca et al. (2017).
(2017), demonstrate the therapeutic potential of optogenetics in
treating arrhythmias.
Recently Nyns et al. (2019) also investigated the therapeutic
potential of an automated hybrid bioelectric system for safe,
precise, repeated, shock free, and on-demand termination of
atrial fibrillation. They first found that arrhythmias that were
induced in ReaChR- expressing-isolated and intact rat hearts,
were terminated via spatially confined epicardial illumination of
the right atrium (20 mm2) using single light pulses (470 nm,
3.5 mW/mm2) of 100ms and 1,000ms durations (Nyns et al.,
2019). Next, they implanted a LED system, controlled by cardiac
rhythm monitor system and triggered by the onset of atrial
fibrillation, in the rat’s thoracic cavities (Nyns et al., 2019). They
demonstrated that 96% of induced atrial fibrillation episodes
were efficiently terminated upon LED activation (470 nm, 3.5
mW/mm2, 500ms); a detailed schematic and experimental set up
of the system is provided in Figure 8. These results suggest that
integration of optogenetic and electrical systems would provide
a novel mechanism for autogenous detection and termination
of arrhythmias. Such a technique could provide an electrical,
shock-free, and anti-fibrillatory therapy which is in high demands
in younger patients suffering with recurrent episodes of atrial
fibrillation (Nyns et al., 2019).
Pre-clinical Drug Development
Cardiotoxicity is one of the primary reasons for drug withdrawal.
In the United States, it contributes to ∼20% of withdrawal at
each phase of drug development and post-market surveillance
process (Piccini et al., 2009; Klimas et al., 2016). Current assays
of evaluating electrophysiology, as a measure of cardiotoxicity
testing, are low throughput, rely on the physical contact, are
difficult to scale up and automate (Ambrosi et al., 2014; Entcheva
and Bub, 2016; Boyle et al., 2018). Thus, efficient high throughput
screening tools for detection of drug-induced cardiotoxicity at
early phase of drug development process would significantly
reduce the cost of the process (Piccini et al., 2009). Klimas
et al. (2016) demonstrated the first automated all optical system
for dynamic cardiac electrophysiology measurement, named
OptoDyCE, for rapid assessment of cardiotoxicity measure of
drug candidates. They tested with ChR2-expressing generic
cardiomyocytes and iPSC-derived cardiomyocytes using voltage-
and calcium-sensitive dyes to enable high-content and high-
throughput acquisition of drug-induced electrophysiological
changes in the action potential and associated calcium transients
(Klimas et al., 2016). In addition, Entcheva et al. also suggested
that such all optical high-throughput system allows precise
probing and monitoring of cell electrophysiology within 3D
constructs or within an intact organs, such as heart (Entcheva
and Bub, 2016). These studies suggest that optogenetics, together
with all optical system, hold potential in pre-clinical evaluation
of cardiotoxicity during drug development through rapid,
contactless and automated procedures for monitoring cellular
functions in a high throughput fashion.
Cell-Cell Coupling
Optogenetics hold great potential in investigating heterocellular
coupling between cardiomyocytes and non-cardiomyocytes, both
on healthy and infarcted hearts (Yu et al., 2017). Investigators
have shown the role of heterocellular coupling between scar
tissue (myofibroblasts) and un-injured cardiomyocytes in situ
following infarction and such couplings are suspected to induce
adverse outcomes, such as arrhythmias (Miragoli et al., 2006;
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FIGURE 6 | Optogenetic pacing of rat hearts in an open chest (left) and a closed chest (right) configurations (A). Apical expression of ChR2 was obtained via
intra-myocardial delivery of transgene-carrying AAV-9 vector in the apex of rat hearts. Two weeks after the transgene delivery photosensitive hearts were illuminated
(Continued)
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FIGURE 6 | with blue light, using LED-coupled fiber optic. For both configurations, ECG recordings show that heart beating rates increase with the flashing frequency
of the light stimulus in a 1:1 ratio. Blue dots in the figure designate blue-light illumination (Scale 1 cm). Cardiac resynchronization therapy using multi-site optogenetic
pacing for isolated rat hearts, expressing ChR2 (B). Two red circles mark ChR2 delivery sites for dual site-optogenetic pacing while white lettered “E” designates the
placement of electrode during electrode pacing (a), optical maps and ECG recordings during: normal sinus rhythm (b), electrical pacing at the apex (c), single-site
optogenetic pacing (d,e), and dual-site optogenetic pacing (f). Three red circles refer ChR2 delivery sites (g), optical maps and ECG recordings during: single-site
electrical pacing (h), and multi-site optogenetic pacing (i). Multi-site optogenetic pacing lowered both the left ventricle activation time (14.8ms, see Optical map) and
also the QRS durations (65ms, see ECG recordings) compared to those values from single-site right ventricular electrical pacing (i.e., 24.5 and 80ms, respectively).
Reproduced with permission from Nussinovitch and Gepstein (2015).
FIGURE 7 | Representative ECG signals of an explanted mice heart, expressing ChR2 (A). Ventricular tachycardia was induced via electrical stimulation (red bar,
50Hz) and was terminated via epicardial illumination with blue light (blue bar, 470 nm, 1 s, 0.4 mW/mm2, 143 mm2 ). Role of illumination parameters, such as duration
(B) and area (C), on arrhythmia termination rate are presented. Reproduced with permission from Bruegmann et al. (2016).
Jacquemet and Henriquez, 2007; Rubart et al., 2017). Quinn
et al. (2016) utilized an optogenetic protein, VSFP2.3, to report
for the first time on the existence of heterocellular electrotronic
coupling between cardiomyocytes and non-cardiomyocytes in
intact transgenic mouse hearts, following cryoinjury. They
provided targeted expression of VSFP2.3 in cardiac cells
of mouse hearts using Cre-lox recombination and cell-type
specific promoters and reported that signals from non-myocyte,
expressing VSFP2.3, at the border of injury were similar
to that of action potential of cardiomyocytes. These results
suggest that optogenetics provide a valuable tool in determining
heterocellular electrotronic coupling between cardiomyocytes
and non-cardiomyocytes in an intact transgenic mouse heart
at healed borders (Figure 9; Quinn et al., 2016); such results
are in agreement with our recent observations from chronically
infarcted mouse hearts that were loaded with a voltage-
sensitive fluorescent dye ANNINE-6plus (Rubart et al., 2017).
In brief, Langendorff-perfused mouse heart, induced with
myocardial infarction injury and stained with ANNINE-6plus,
were electrically paced (3Hz) at remote regions and the
fluorescence data, indicating the transmembrane voltages, in
the myocytes and adjacent non-myocytes were recorded using
multiple line-scan acquisition data (Figure 9; Rubart et al., 2017).
We also observed that transmembrane potential in non-myocytes
fluctuates in phase with myocytes (1:1 ratio), which infers that
non-myocytes were electrically coupled with cardiomyocytes
in infarct border via heterocellular coupling (Figure 9; Rubart
et al., 2017). However, some of the potential advantages of
using optogenetic proteins (e.g., VSFP2.3), instead of organic
dyes for such applications, would be their non-toxicity, non-
cardiotoxicity, and feasibility of performing repeated in situ
observations on target cells for a longer period of time (Chang
Liao et al., 2015; Koopman et al., 2017).
Enhanced coupling between cardiomyocytes and non-
cardiomyocytes after myocardial injury is mediated by
phenotypic changes in the fibroblasts, which results in an
increased connexin expression and also in an emergence
of nanotubes-like structures between the cell types (Quinn
et al., 2016; Yu et al., 2017). Determination of heterocellular
coupling is also useful in assessing the electrophysiological
maturity of stem-cell derived cardiomyocytes (e.g., iPSC-CM)
following transplantation, since electrical coupling between
transplanted cells and native cardiomyocytes may indicate
the conductivity and the functionality of the graft in the
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FIGURE 8 | An automated hybrid bioelectric system for the restoration of sinus rhythm during atrial fibrillation. The autogenous bioelectric system comprises of an
opsin expressing right atrium (green), a cardiac rhythm monitor, and ECG electrodes, where the ECG signal is fed as input to the cardiac monitor (A). Abnormalities in
ECG recordings, such as during atrial fibrillation, causes an output signal that triggers ON the implantable LED device (500ms) which activates ReaChR in the atrium;
the activation of the latter terminates fibrillation and restores normal sinus rhythm. Detail on the LED assembly (B), experimental details on LED implantation
procedures, before (C) and after the chest closure (D), respectively, are illustrated. LED is held firmly on the thoracic wall and on the top of the right atrium without any
physical contact to the heart (C). Electrical wires for pacing and turning on LED are shown in (D). Reproduced with permission from Nyns et al. (2019).
recipient tissue (Boyle et al., 2018). Thus, optogenetics can
greatly aid in the in situ understanding of heterocellular
coupling in the normal, diseased, or tissue-engineered
cardiac tissues.
Modulation of Cell Signaling
Optogenetics is not only limited to the use of light-sensitive ion
channels and pumps but the field is also being driven toward
other light-sensitive proteins, such as G-protein modulating
opsins (Table 1; Ferenczi et al., 2019). In cardiac research,
both natural and engineered versions of these opsins are being
investigated to activate cell signaling with high temporal and
spatial precision (Ferenczi et al., 2019). A recent study by
Makowka et al. (2019) has reported the utility of jellyfish
opsin (JellyOp) to activate Gs signaling in cardiomyocyte
embryoid bodies and also in the intact mice hearts. Upon
stimulation of JellyOp embryoid bodies with blue light (470 nm,
2.9 mW mm−2, 5min), cAMP levels were increased for up
to 646% of the baseline levels (Makowka et al., 2019). In
addition, beating rates of the embryoid bodies and of the
intact transgenic mice hearts were increased upon optogenetic
stimulation (Makowka et al., 2019). Similar effects were observed
in JellyOp control groups, stimulated with pharmacologic
agents; however, light termination render significantly faster
recovery to the baseline states in the transgenic groups when
compared to wash out of isoprenaline in the control groups
(Makowka et al., 2019). In another recent study, Repina
et al. investigated the optogenetic control of canonical Wnt
signaling (OptoWnt) via optical stimulation of hESC expressing
photoreceptor Cryptochrome 2, fused to Wnt co-receptor LRP6
(Repina et al., 2019). They examined that OptoWnt caused
reduced expression of pluripotency markers but produced
concomitant increment in mesendoderm differentiation (Repina
et al., 2019). Interestingly, they also reported that optogenetics
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FIGURE 9 | Entrainment of the membrane potential of non-cardiomyocytes by ventricular cardiomyocytes in an infarct border of a Langendorff-perfused mouse heart
(A–G). Mouse hearts were genetically engineered to express cardiomyocyte-specific EGFP to identify cardiomyocytes from non-cardiomyocytes. Prior two-photon
(Continued)
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FIGURE 9 | laser scanning microscopy (TPLSM), harvested transgenic hearts were loaded with voltage-sensitive fluorescence dye (ANNINE-6plus). Isolated hearts
were electrically paced (3Hz) at remote regions and fluorescence data in the myocytes and adjacent non-myocytes were recorded using multiple line-scan acquisition
system across the tissue. A line crossing over cardiomyocytes and non-cardiomyocytes (A, dotted line) was repeatedly scanned to acquire line scan fluorescence
F(x,t) (B). Traces showing 1F/Fo (C) were generated from line-scan data; black trace denotes signal from cardiomyocytes (from black bracket in A) while red trace
denotes signals from adjacent non-myocytes (from red bracket in B). Magnified section (F) and successive readings (G). Transmembrane potential in both these cell
types are in phase (1:1 ratio) suggesting the heterocellular electric coupling between myofibroblasts and cardiomyocytes in the infarct border. Reproduced with
permission from Rubart et al. (2017). Evidence of such heterocellular coupling between cardiomyocytes and non-cardiomyocytes in the scar border is also evident
from a study by Quinn et al. (H). Intact transgenic mouse hearts where non-cardiomyocytes, selectively made to express VSFP2.3, showed enhanced electrical
activity, as observed by YFP signal in the scar border. Reproduced with permission from Quinn et al. (2016).
enabled activation of Wnt signaling in subpopulation of
cells which also showed cell self-organization in 2D and
3D cultures, mimicking the phases of human gastrulation
(Repina et al., 2019). Similarly, another earlier work by Beiert
et al. (2014) showed that illumination of cardiomyocytes
expressing melanopsin (a light-activated Gq coupled receptor
found in the photosensitive ganglion cells of the retina)
(Berson et al., 2002; Qiu et al., 2005) increased their beating
rates and induced a local pacemaker activity within the
illuminated regions (Beiert et al., 2014). These studies show
that optogenetics also hold great potential in deciphering the
temporal and spatial role of cell signaling in cardiac research
and morphogenesis.
FUTURE DIRECTIONS
Despite these advances, cardiac optogenetics is still in a nascent
stage for clinical translation (Gruber et al., 2018). One key
approach to move closer to human application would be in
scaling up the system to larger animal models, such as pig,
which would better mimic human heart anatomy (Boyle et al.,
2018). In specific, both the genetic engineering tools (for
appropriate opsin variant types, opsin characteristics, methods,
and levels of opsin expression) and also the optical systems
(for appropriate source and mode of light delivery, pulse
characteristics, illumination area, duration, and intensity) should
be optimally determined in these larger animal models (Nyns
et al., 2019). Next, emphasis should also be given to the in
silico approaches that provide appealing tools in modeling
different systems, such as heterogeneity in opsin expression,
light absorption, illumination pattern, and in scaling up the
system to meet clinically relevant sizes and also in predicting
the outcomes accordingly (Boyle et al., 2013; Karathanos et al.,
2016). On the other hand, since most of the present day
observations are obtained from unconscious and immobilized
animal models, another strategy to advance toward translational
medicine would be to develop technologies feasible on freely
moving and conscious experimental animals; such models
would best mimic the native physiological states (Gruber
et al., 2018). Furthermore, integration of recent developments
on biocompatible integumentary membrane and micro LED
array can expedite development of optogenetic membrane
that can contract along the myocardial surface and provide
optical stimulation at multiple locations simultaneously; such
technology is particularly appealing for optogenetic defibrillation
method that requires stimulation of a larger myocardial area
(Boyle et al., 2015).
One of the key considerations for clinical application
of cardiac optogenetics is on the safe, stable, and uniform
opsin expression in human heart (Pianca et al., 2017).
Concerns of toxicity and immunogenicity may arise with opsin
expression in cardiac applications that requires high opsin
levels for robust photocurrents (Boyle et al., 2015; Gruber
et al., 2018). Besides, safe and appropriate vehicle types and
administration routes must be well-established for intended
applications (Ambrosi et al., 2014). In this regard, although
many novel technologies are emerging to address such needs,
they are yet to be validated in appropriate animal models.
For instance, tandem cell unit has only been validated in in
vitro settings because of possible issues of cell engraftment
and host-graft coupling for in vivo applications (Pianca et al.,
2017; Gruber et al., 2018). Next, possible concerns of non-
uniform opsin expression (which may render heterogeneous
cell depolarization and induce substrate for arrhythmias),
ectopic opsin expression and immune concerns with host-
specific antibodies to viral vectors, etc. need to be explored
in depth in clinically relevant larger animal models (Pianca
et al., 2017). Thus, clinically acceptable vehicle, delivery method,
safe level, and retention period of opsin expression, all
should be carefully determined. Fortunately, highly efficient
and safer transgene knock in strategies such as CRISPR/Cas9
system are being highly investigated recently. Applications
of such advanced genetic engineering methods would greatly
reduce barriers of non-uniform or ectopic opsin expression
with conventional strategies for cardiovascular research and
regenerative medicine.
Another concern with the clinical translation of optogenetics
is the limitations on light penetration due to highly dense
and light-scattering cardiac tissues, specifically with applications
of blue light for the excitation of ChR2 opsins (Entcheva,
2013; Boyle et al., 2015). Potential alternatives to such issues
are applications of: (1) red-shifted optogenetic proteins to
increase light penetration depth, (2) ultrathin LEDs to maintain
beam shape and minimize light scattering, (3) bioluminescence
techniques to fuse opsin with luciferase and eliminate the need
of external light illumination, (4) opsins co-expressed with
sonoluminescent or x-ray inducible nanophosphors to release
visible light in situ and reduce light attenuation, and (5) up-
conversion nanoparticles to convert highly tissue penetrable near
infrared waves to visible light (Entcheva, 2013; Boyle et al., 2015,
2018; Jiang et al., 2017). Another area that demands thorough
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investigation is on the energy requirements of optogenetic-
based therapies for cardiovascular applications. The overall
energy for an optogenetic-based therapy is influenced by light
penetration, optical properties of the tissues, level, pattern,
and functionality of opsin expression, and the physiological
properties of the host cells/tissues, making it difficult to predict
the energy requirements for in vivo applications (Entcheva,
2013). Despite these considerations, encouraging in vitro and in
vivo studies have provided proof-of concept for the translational
potential of cardiac optogenetics. In addition, emerging scope
of optogenetics in modulating the dynamic roles of signaling
moieties needed during crucial biological functions, such as cell
signaling, differentiation andmigration are greatly expanding the
dimensions of in vitro and in vivo research. Future investigations
on such emerging scopes would greatly enhance the clinical
success of the field for cardiovascular regenerative medicine.
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